Physician profile
Christopher Puckett
NPI 1679060388
$5,739.16
in general payments reported to CMS, 2019-2025
27 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $1,598 · 2023: $1,502 · 2024: $1,239 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936 · Entertainment: $13.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,935.83 |
| Entertainment | $13.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,551.72 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $674.72 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $454.54 | 2022-2025 | |
| Amgen INC. | $427.52 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $397.31 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $367.52 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $224.00 | 2022-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.89 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.15 | 2022-2025 | Xifaxan |
| Dynavax Technologies Corporation | $189.33 | 2022-2025 | Heplisav-B |
| Abbvie INC. | $135.95 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $126.32 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $99.03 | 2021-2022 | |
| Exact Sciences Corporation | $97.00 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $78.29 | 2023-2024 | Veozah, Myrbetriq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $69.31 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $68.46 | 2022-2023 | Livalo, Seglentis |
| Sumitomo Pharma America, INC. | $63.09 | 2024-2025 | Gemtesa |
| Sanofi Pasteur INC. | $58.89 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $54.41 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.35 | 2024-2025 | Caplyta |
| Daiichi Sankyo INC. | $38.44 | 2021-2022 | |
| Dexcom, INC. | $23.32 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $20.23 | 2022 | |
| Axsome Therapeutics, INC. | $19.84 | 2023 | Sunosi |
| Novartis Pharmaceuticals Corporation | $19.76 | 2022 | |
| Optos, INC. | $13.77 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Puckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.